SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-17-051546
Filing Date
2017-08-14
Accepted
2017-08-14 08:52:24
Documents
43
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a17-18917_110q.htm 10-Q 871249
2 EX-31.1 a17-18917_1ex31d1.htm EX-31.1 11032
3 EX-31.2 a17-18917_1ex31d2.htm EX-31.2 11032
4 EX-32.1 a17-18917_1ex32d1.htm EX-32.1 7717
  Complete submission text file 0001104659-17-051546.txt   3065859

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT dova-20170630.xml EX-101.INS 318469
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dova-20170630.xsd EX-101.SCH 33424
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dova-20170630_cal.xml EX-101.CAL 23703
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT dova-20170630_lab.xml EX-101.LAB 328055
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dova-20170630_pre.xml EX-101.PRE 249223
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dova-20170630_def.xml EX-101.DEF 159651
Mailing Address 2530 MERIDIAN PARKWAY SUITE 300 DURHAM NC 27713
Business Address 2530 MERIDIAN PARKWAY SUITE 300 DURHAM NC 27713 919-806-4487
Dova Pharmaceuticals, Inc. (Filer) CIK: 0001685071 (see all company filings)

IRS No.: 813858961 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38135 | Film No.: 171027445
SIC: 2834 Pharmaceutical Preparations